

Important Update DCH Decision Document

**Listed below are Preferred Drug List changes for the State of Georgia
Fee-For-Service Medicaid and PeachCare for Kids Programs**

EFFECTIVE July 1, 2016 (see chart below)

DCH rebate vendor Goold Health Systems (GHS) has reviewed SFY2017 supplemental rebate offers with DCH and reviewed the below drug categories at the March 2016 DURB meeting. The PDL decisions or PDL changes for new drugs or categories reviewed during the March DURB meeting are outlined below. **Those drugs highlighted in red indicate a change from current PDL status.** For a full listing of our PDL, go to www.dch.georgia.gov/pharmacy and select the “preferred product list” option.

ONLY DRUGS with Supplemental Rebate Offer or reviewed during the March DURB as either new to market or a change in PDL status are listed	PREFERRED AGENTS	NON-PREFERRED AGENTS
ADHD AGENTS		
	FOCALIN, XR	ADDERALL XR
	KAPVAY	DEXEDRINE TAB, CAP ER
	METHYLIN SOLN	DIYANAVEL XR
	METHYLPHENIDATE LA	PROCENTRA (ORAL) SOLUTION
	QUILLIVANT XR	
	QUILLICHEW	
	VYVANSE	
AHF, RECOMBINANT		
	ADVATE	ADYNOVATE
	HELIXATE FS	NUWIQ
	NOVOEIGHT	<i>Non-Preferred</i> status with <i>Prior Authorization and Grandfathering</i> at this time for all other agents in the class
ANTIHEMOPHILIC PRODUCTS-vWF		
	WILATE	<i>Non-Preferred</i> status with <i>Prior Authorization</i> and Grandfathering at this time for all other agents in the class
ANTIHEMOPHILIC PRODUCTS FACTOR IX RECOMBINANT		
	BENEFIX	<i>Non-Preferred</i> status with <i>Prior Authorization and Grandfathering</i> at this time for all other agents in the class
AMINOGLYCOSIDES FOR CYSTIC FIBROSIS		
	KITABIS PAK	BETHKIS
		TOBI PODHALER

ONLY DRUGS with Supplemental Rebate Offer or reviewed during the March DURB as either new to market or a change in PDL status are listed	PREFERRED AGENTS	NON-PREFERRED AGENTS
ANTICOAGULANTS		
	ELIQUIS	LOVENOX
	PRADAXA	SAVAYSA
	XARELTO	
ANTICONVULSANTS		
	LYRICA CAPS	APTIOM
	OXTELLAR XR	LYRICA SOLN
	VIMPAT	
ANTICONVULSANTS - BENZODIAZEPINES		
	DIASTAT	ONFI TAB, SUSP
ANTIHYPERLIPIDEMICS, PCSK9I		
	REPATHA	PRALUENT
ANTI-INFLAM,ANTIRHEUM ANTIMETAB		
		RASUVO
ANTIVIRALS, HEPATITIS C DAAS		
	HARVONI	DAKLINZA
	SOVALDI	OLYSIO
	TECHNIVIE	
	VIEKIRA PAK	
	ZEPATIER	
BIOLOGIC IMMUNOMODULATORS		
	COSENTYX	XELJANZ
	ENBREL	
	HUMIRA	
CV- ANGIOTENSIN RECPTOR BLOCKERS		
		DIOVAN
CV- BETA BLOCKERS		
		BYSTOLIC
CV-ANGIOTENSIN MODULATOR/NEPRILYSIN INHIBITOR		
		ENTRESTO
DERM, HYDROCORTISONE SOLN		
		TEXACORT
DERM, NSAIDS		
		FLECTOR
DERM, SCABICIDES,PEDICULOCIDES		
	NATROBA	
	SKLICE	
FIBROMYALGIA AGENTS		
		SAVELLA
GI- DIGESTIVE ENZYMES		
	CREON	PERTZYE
		ZENPEP
GI- INFLAMMATORY BOWEL AGENTS		
	APRISO	LIALDA
	PENTASA	
	CANASA	
GI- LAXATIVES		
	PREPOPIK	
GROWTH HORMONE		

ONLY DRUGS with Supplemental Rebate Offer or reviewed during the March DURB as either new to market or a change in PDL status are listed	PREFERRED AGENTS	NON-PREFERRED AGENTS
	GENOTROPIN	ZOMACTON
	NORDITROPIN FLEXPRO	
	NUTROPIN AQ	
OPHTHALMICS, ADRENERGIC AGENTS		
	SIMBRINZA	
OPHTHALMICS ANTIALLERGICS		
	PAZEO	
OPHTHALMIC ANTIBIOTICS - QUINOLONES		
	MOXEZA	
	VIGAMOX	
OPHTHALMIC NSAIDS		
	ILEVRO	
OPHTHALMICS PROSTAGLANDINS		
		TRAVOPROST
OPHTHALMICS STEROID ANTIBIOTIC COMBINATIONS		
	TOBRADEX, ST	
OPHTHALMIC STEROIDS		
	DUREZOL	
PHOSPHATE BINDER AGENTS		
	PHOSLYRA	CALCIUM ACETATE CAP
	RENAGEL	FOSRENOL
		VELPHORO
VASOPROTECTANTS		
		CORLANOR